Publication

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study

Cruijsen, M., van der Velden, W. J. F. M., de Haan, A. F. J., Klein, S. K., Hoogendoorn, M., Tromp, Y., de Valk, B., van Rees, B., de Boer, F., van der Spek, E., Pruijt, J., Verdonck, L. F., Vellenga, E., Blijlevens, N., van de Loosdrecht, A. A. & Huls, G., 8-Jun-2020, In : Leukemia & Lymphoma. p. 1-4 4 p.

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

APA

Cruijsen, M., van der Velden, W. J. F. M., de Haan, A. F. J., Klein, S. K., Hoogendoorn, M., Tromp, Y., ... Huls, G. (2020). Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study. Leukemia & Lymphoma, 1-4. https://doi.org/10.1080/10428194.2020.1775217

Author

Cruijsen, M ; van der Velden, W J F M ; de Haan, A F J ; Klein, S K ; Hoogendoorn, M ; Tromp, Y ; de Valk, B ; van Rees, B ; de Boer, F ; van der Spek, E ; Pruijt, J ; Verdonck, L F ; Vellenga, E ; Blijlevens, N ; van de Loosdrecht, A A ; Huls, G. / Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study. In: Leukemia & Lymphoma. 2020 ; pp. 1-4.

Harvard

Cruijsen, M, van der Velden, WJFM, de Haan, AFJ, Klein, SK, Hoogendoorn, M, Tromp, Y, de Valk, B, van Rees, B, de Boer, F, van der Spek, E, Pruijt, J, Verdonck, LF, Vellenga, E, Blijlevens, N, van de Loosdrecht, AA & Huls, G 2020, 'Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study', Leukemia & Lymphoma, pp. 1-4. https://doi.org/10.1080/10428194.2020.1775217

Standard

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study. / Cruijsen, M; van der Velden, W J F M; de Haan, A F J; Klein, S K; Hoogendoorn, M; Tromp, Y; de Valk, B; van Rees, B; de Boer, F; van der Spek, E; Pruijt, J; Verdonck, L F; Vellenga, E; Blijlevens, N; van de Loosdrecht, A A; Huls, G.

In: Leukemia & Lymphoma, 08.06.2020, p. 1-4.

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Vancouver

Cruijsen M, van der Velden WJFM, de Haan AFJ, Klein SK, Hoogendoorn M, Tromp Y et al. Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study. Leukemia & Lymphoma. 2020 Jun 8;1-4. https://doi.org/10.1080/10428194.2020.1775217


BibTeX

@article{6f5894967d1d40a0a479356e1e47405c,
title = "Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study",
keywords = "RISK MYELODYSPLASTIC SYNDROMES, CANCER, MDS",
author = "M Cruijsen and {van der Velden}, {W J F M} and {de Haan}, {A F J} and Klein, {S K} and M Hoogendoorn and Y Tromp and {de Valk}, B and {van Rees}, B and {de Boer}, F and {van der Spek}, E and J Pruijt and Verdonck, {L F} and E Vellenga and N Blijlevens and {van de Loosdrecht}, {A A} and G Huls",
year = "2020",
month = "6",
day = "8",
doi = "10.1080/10428194.2020.1775217",
language = "English",
pages = "1--4",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "TAYLOR & FRANCIS LTD",

}

RIS

TY - JOUR

T1 - Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands

T2 - the OCEAN study

AU - Cruijsen, M

AU - van der Velden, W J F M

AU - de Haan, A F J

AU - Klein, S K

AU - Hoogendoorn, M

AU - Tromp, Y

AU - de Valk, B

AU - van Rees, B

AU - de Boer, F

AU - van der Spek, E

AU - Pruijt, J

AU - Verdonck, L F

AU - Vellenga, E

AU - Blijlevens, N

AU - van de Loosdrecht, A A

AU - Huls, G

PY - 2020/6/8

Y1 - 2020/6/8

KW - RISK MYELODYSPLASTIC SYNDROMES

KW - CANCER

KW - MDS

U2 - 10.1080/10428194.2020.1775217

DO - 10.1080/10428194.2020.1775217

M3 - Comment/Letter to the editor

C2 - 32530341

SP - 1

EP - 4

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -

ID: 132001392